Luminescence imaging technology developer Lightpoint Medical has signed a collaboration agreement with radiopharmaceutical developer Telix Pharmaceuticals.
Under the agreement, the two firms will seek to integrate Lightpoint's Sensei gamma probe with Telix's investigational SPECT imaging agent TLX599-CDx for intraoperative prostate cancer detection. The companies have the intention of regulatory approval and marketing of a combined product, Lightpoint said.
Sensei is a small surgical gamma probe for robot-assisted cancer surgery. It has been approved for marketing in the U.S., the European Union, the U.K, and Australia, according to Lightpoint.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
